Citius Pharmaceuticals updates corporate presentation; reiterates LYMPHIR Q4 2025 launch and pipeline progress

Citius Pharmaceuticals, Inc.

LYMPHIR (denileukin diftitox-cxdl) FDA approved for CTCL; commercial launch planned Q4 2025.
Mino-Lok Phase 3 completed with positive topline data meeting primary and secondary endpoints.
Halo-Lido Phase 2b completed; only prescription therapy under development for hemorrhoids.
Citius Oncology (CTOR) spun off August 2024; CTXR intends to distribute CTOR shares to CTXR shareholders.
Over $90M invested in LYMPHIR; new J-code (J9161) and NCCN guidelines inclusion secured.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.